Publication date: Jun 28, 2023
Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved in several regions for the treatment of anemia of chronic kidney disease (CKD). ASPEN evaluated the efficacy, safety, and feasibility of roxadustat in patients with anemia of CKD in US dialysis organizations. This open-label, single-arm study (NCT04484857) comprised a 6-week screening period, followed by 24 weeks of treatment (with optional extension ≤1 year) and a 4-week follow-up. Patients aged ≥18 years, receiving chronic dialysis, with hemoglobin (Hb) 9. 0-12. 0 g/dL if converting from erythropoiesis-stimulating agents (ESAs), or
| Concepts | Keywords |
|---|---|
| Aspen | anemia |
| Dialysis | drugs and dialysis |
| Nct04484857 | outcomes research |
| Optional | |
| Week |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Roxadustat |
| disease | MESH | anemia |
| disease | MESH | chronic kidney disease |
Original Article
(Visited 1 times, 1 visits today)